查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008679

肺炎治疗市场：2026年至2032年全球市场预测（依治疗方法、给药途径、病患年龄层、病原体、通路和适应症划分）

Pneumonia Therapeutics Market by Therapy Type, Route Of Administration, Patient Age Group, Pathogen Type, Distribution Channel, Indication Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺炎治疗市场价值将达到 181.9 亿美元，到 2026 年将成长至 198.8 亿美元，到 2032 年将达到 368 亿美元，复合年增长率为 10.59%。

主要市场统计数据
基准年 2025 181.9亿美元
预计年份：2026年 198.8亿美元
预测年份 2032 368亿美元
复合年增长率 (%) 10.59%

为相关人员提供关于正在重新定义肺炎治疗格局的临床、监管和商业趋势的全面策略概述。

本报告整合了最新的临床趋势、监管变化和不断演进的医疗服务模式，阐明了肺炎治疗的现状，这些因素正在重新定义相关人员的优先事项。分析概述了影响研究挑战、产品开发策略和病患管理路径的关键驱动因素，同时重点阐述了科学创新与医疗保健系统需求之间的交集。

识别科学创新、医疗服务模式和报销环境方面的变革性变化，这些变化正在加速整个肺炎治疗流程的变革。

科学、医疗服务和资金筹措的变革性变化正在为肺炎治疗的创新开闢新的途径。生物製药和免疫调节疗法的进步正在拓展传统抗感染药物以外的治疗选择，而对病原体和宿主反应更精准的理解则推动了更具针对性的研发策略。同时，医疗服务也变得更加分散化。门诊治疗、居家氧气疗法和远距监测正在减轻住院患者的负担，并改变治疗方法的选择和实施方式。

分析 2025 年美国对肺炎治疗药物征收关税措施的累积经济、供应链和临床取得影响。

美国2025年实施的关税调整的累积影响将对肺炎治疗的供应链、筹资策略和临床取得途径产生多方面的影响。进口原材料、呼吸设备组件或成品药关税的提高可能导致生产成本上升，并挤压拥有全球分散供应链的製造商的利润空间。这种压力往往迫使製造商采取成本削减措施，例如供应商多元化、关键组件近岸外包以及重新谈判供应商合同，以维持生产的连续性和产品的价格竞争力。

关键细分洞察揭示了治疗方法类型、给药途径、分销管道、患者年龄层、病原体特征和适应症类别之间的相互作用。

一套精细的细分框架揭示了治疗差异化和商业性机会如何跨越治疗方法类型、给药途径、分销管道、患者年龄层、病原体类型和适应症等要素相互交织。治疗方法类型包括辅助性治疗（如皮质类固醇和雾化器）；感染疾病物（包括抗生素、抗真菌药物和抗病毒药物，其中抗生素细分为Aminoglycosides、β-内酰胺类、大环内酯类、奎诺酮和四环霉素）；生物製药（包括免疫调节剂和单克隆抗体）；以及以氧疗、机械通气和氧气疗法治疗为中心的辅助治疗。这些区分至关重要，因为作用机制、安全性以及所需的临床环境决定了治疗方法在从急性护理到门诊护理的连续过程中所处的位置。

深入分析美洲、欧洲、中东和非洲以及亚太地区如何塑造临床实践、进入途径和创新重点。

区域趋势显着影响着美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、治疗药物的可及性以及创新疗法的采纳顺序。在美洲，医疗保健系统和支付方生态系统优先考虑临床疗效和成本效益的证据，鼓励采用疗效已证实且具有显着经济价值的疗法。此外，特定市场的过渡期照护模式和门诊环境正在加速吸入和口服药物的推广应用，从而实现早期出院和居家照护。

重点介绍领先的肺炎治疗研发公司的策略定位、产品线差异化、合作伙伴关係和商业化策略。

在企业层面，发展趋势不再只取决于单一产品的上市，而是更重视产品线差异化、策略伙伴关係和商业化敏捷性。授权协议和联合开发伙伴关係常被用于优化临床应用路径，并加速取得快速诊断和吸入给药平台等互补技术，从而缩短产品上市时间。将标靶抗感染疾病项目与辅助生物製药製剂结合的研发公司，能够满足多样化的临床需求，同时建构多条展现价值的途径。

为行业领导者提供切实可行的策略建议，以优化肺炎治疗的临床开发、供应弹性、报销谈判和患者获取途径。

产业领导者必须推动一系列切实可行且影响深远的倡议，以在保持药品可及性和可负担性的同时，持续推动创新。首先，将卫生经济学终点指标和真实世界数据（REW）收集纳入临床开发项目，并使其与支付方的证据要求保持一致，将简化报销谈判流程，并加速在各种医疗环境中的推广应用。其次，透过供应商多元化、确保区域生产能力和策略性库存管理来增强供应链韧性，将降低贸易中断和物流延误对药品和医疗设备供应的影响。

透明的调查方法，描述了肺炎治疗评估中使用的资料来源、检验方法、相关人员访谈和分析框架。

本研究采用多方面方法，结合与关键相关人员的对话、整合二手文献以及反覆检验，以确保获得可靠且可操作的见解。资料来源包括已发表的临床文献、监管指导文件、医疗设备和治疗方法的技术摘要、不同医疗保健系统的采购政策以及揭示公司策略行动的公开文件。透过对临床医生、医院采购负责人、生命週期管理专家和销售经理的结构化访谈收集关键讯息，从而获得有关营运挑战和产品推广驱动因素的具体背景资讯。

一项综合分析，旨在为参与肺炎治疗药物研发和推广的相关人员确定策略挑战、风险缓解策略和机会途径。

总之，本分析整合了各项研究结果，并提出了一系列策略挑战，旨在指南各组织在肺炎治疗领域实现以患者为中心的永续解决方案。在供应链和贸易逆风的情况下，必须将对标靶治疗和支持性护理的投资与切实可行的运作策略相结合，以维持治疗的可及性。同时，获得强有力的证据来证明其临床和经济价值，将是促进其在不同医疗机构中广泛应用的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法分類的肺炎治疗市场

  • 辅助性治疗
    • 皮质类固醇
    • 喷雾器
  • 抗感染药物
    • 抗生素
      • Aminoglycosides
      • β-内酰胺
      • 大环内酯类
      • 奎诺酮
      • 四环霉素
    • 抗真菌药物
    • 抗病毒药物
  • 生物製药
    • 免疫调节剂
    • 单株抗体
  • 支持性护理
    • 点滴管理
    • 人工呼吸
    • 氧气疗法

第九章 肺炎治疗市场：依给药途径划分

  • 吸入
  • 静脉注射
  • 口服

第十章：依患者年龄层分類的肺炎治疗药物市场

  • 成人版
  • 老年人
  • 儿童

第十一章 以病原体分類的肺炎治疗药物市场

  • 非典型
    • 衣原体
    • 退伍军人菌
    • 霉浆菌
  • 细菌
  • 真菌
  • 病毒性的

第十二章 肺炎治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 肺炎治疗药物市场（依适应症划分）

  • 社区传播
  • 院内感染
  • 人工呼吸器相关

第十四章 肺炎治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肺炎治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肺炎治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肺炎治疗市场

第十八章：中国肺炎治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Allergan plc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biobrick Pharma
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Lincoln Pharmaceuticals Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus UK Limited by CSL Limited
  • Serum Institute of India
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Wellona Pharma
  • Zydus Healthcare Limited
Product Code: MRR-8E22B61932B6

The Pneumonia Therapeutics Market was valued at USD 18.19 billion in 2025 and is projected to grow to USD 19.88 billion in 2026, with a CAGR of 10.59%, reaching USD 36.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.19 billion
Estimated Year [2026] USD 19.88 billion
Forecast Year [2032] USD 36.80 billion
CAGR (%) 10.59%

Comprehensive strategic introduction to the evolving clinical, regulatory, and commercial dynamics that are redefining pneumonia therapeutics for stakeholders

The introduction establishes the current state of pneumonia therapeutics through a synthesis of contemporary clinical developments, regulatory shifts, and evolving delivery models that are redefining stakeholder priorities. This narrative frames the principal drivers shaping research agendas, product development strategies, and patient management pathways while emphasizing the intersection of scientific innovation and healthcare system needs.

By situating therapeutic advances alongside changing care environments, this opening analysis clarifies how new mechanisms of action, adjunctive care approaches, and supportive technologies are influencing clinical decision making. It also highlights the crucial role of cross-functional collaboration among clinicians, payers, manufacturers, and supply chain partners in converting scientific promise into improved patient outcomes. Transitioning from a descriptive baseline, the introduction sets up subsequent sections to explore structural shifts, regulatory and trade pressures, segmentation nuances, regional dynamics, and strategic responses that will determine near-term trajectories for pneumonia therapeutics.

Identification of transformative shifts in scientific innovation, care delivery models, and reimbursement landscapes that are accelerating change across pneumonia therapeutic pipelines

Transformative shifts across science, care delivery, and financing are converging to create new pathways for innovation in pneumonia therapeutics. Advances in biologics and immune modulation are expanding therapeutic options beyond traditional anti-infectives, while the precision characterization of pathogens and host responses is driving more targeted development strategies. At the same time, care delivery is decentralizing: outpatient management, home oxygen and remote monitoring reduce inpatient burden and change how therapies are chosen and delivered.

Concurrently, payer and reimbursement models increasingly reward clinical outcomes and value-based approaches, which pressures developers to demonstrate differentiated benefits beyond pathogen clearance. Digital health tools and real-world evidence are being integrated into regulatory and reimbursement dialogues, accelerating adaptive trial designs and post-approval evidence generation. As a result, scientific innovation, care model evolution, and financing mechanisms are collectively reshaping prioritization across discovery, clinical development, and commercialization, requiring integrated strategies that balance efficacy, access, and economic sustainability.

Analysis of the cumulative economic, supply chain, and clinical access implications stemming from United States tariff actions in 2025 for pneumonia therapeutics

The cumulative effects of tariff adjustments enacted by the United States in 2025 create a multi-dimensional impact on pneumonia therapeutic supply chains, procurement strategies, and clinical access pathways. Increased duties on imported raw materials, components for respiratory devices, or finished pharmaceuticals can raise production costs and compress margins for manufacturers whose supply chains are globally distributed. This pressure often prompts cost mitigation responses such as supplier diversification, nearshoring of critical components, and renegotiation of supplier contracts to preserve manufacturing continuity and product affordability.

Beyond direct cost effects, tariffs can alter logistics and lead times for critical inputs such as APIs, single-use device components, and specialized medical equipment used in oxygen therapy and mechanical ventilation. These disruptions have downstream clinical implications when hospitals and procurement teams encounter variability in availability or elevated pricing that affects formulary decisions and stocking policies. Moreover, tariff-driven changes incentivize stronger supplier qualification processes, increased inventory buffers, and strategic stockpiling for critical items. In parallel, payers and health systems may intensify scrutiny of total cost of care, accelerating shifts toward therapeutics and delivery models that demonstrate durable clinical and economic value. In aggregate, the 2025 tariff dynamics pressure manufacturers to redesign supply networks and strengthen commercial arguments for value and access while health systems adapt procurement strategies to maintain clinical readiness.

Critical segmentation insights revealing how therapy types, administration routes, distribution channels, patient age cohorts, pathogen profiles, and indication categories interact

A nuanced segmentation framework illuminates where therapeutic differentiation and commercial opportunity intersect across therapy type, administration route, distribution channel, patient age group, pathogen type, and indication. Therapy type spans adjunctive therapies that include corticosteroids and device-based nebulizers, anti-infectives composed of antibiotics, antifungals, and antivirals with antibiotics further detailed into aminoglycosides, beta lactams, macrolides, quinolones, and tetracyclines, biologics that encompass immune modulators and monoclonal antibodies, and supportive therapies oriented around fluid management, mechanical ventilation, and oxygen therapy. These distinctions matter because mechanism of action, safety profiles, and required clinical settings determine where a therapy sits along the acute care to outpatient continuum.

Route of administration-covering inhalation, intravenous, and oral delivery-directly affects adherence, ease of outpatient management, and the complexity of supply logistics. Distribution channels ranging from hospital pharmacy to online and retail pharmacy shape go-to-market approaches, pricing strategies, and patient access pathways. Patient age groups, including adult, geriatric, and pediatric cohorts, demand tailored safety and dosing strategies and influence trial design and labeling priorities. Pathogen type segmentation, which includes atypical organisms subdivided into Chlamydophila, Legionella, and Mycoplasma, as well as bacterial, fungal, and viral causes, drives diagnostic requirements and targeted therapeutic development. Finally, indication type such as community acquired, hospital acquired, and ventilator associated pneumonia creates distinct clinical management algorithms, differing regulatory expectations, and variable pathways to adoption. Collectively, this segmentation matrix provides a roadmap for aligning R&D focus, clinical trial populations, and commercialization plans with unmet needs and operational realities.

In-depth regional insights on how Americas, Europe Middle East and Africa, and Asia-Pacific are each shaping clinical practice, access pathways, and innovation priorities

Regional dynamics exert a strong influence on clinical practice patterns, access to therapeutics, and the sequencing of innovation adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems and payer ecosystems emphasize evidence of clinical benefit and cost-efficiency, which incentivizes therapeutics with demonstrable outcomes and robust economic value propositions. Transitional care models and outpatient capabilities in certain markets also accelerate adoption of inhaled and oral regimens that facilitate earlier discharge and home-based care.

Europe, Middle East & Africa present heterogenous regulatory and reimbursement landscapes where centralized guidelines coexist with national-level variations in uptake and procurement. This mosaic drives the need for flexible regulatory strategies, regionally tailored clinical evidence packages, and differentiated pricing approaches. Asia-Pacific encompasses a spectrum from highly sophisticated healthcare markets to rapidly developing systems where access, local manufacturing capacity, and public health priorities shape adoption. Across these regions, differences in pathogen prevalence, diagnostic infrastructure, and hospital capacity influence the relative demand for biologics, targeted anti-infectives, and supportive technologies. Taken together, these regional characteristics require companies to deploy tailored regulatory engagement, supply planning, and evidence generation strategies that align with local clinical practices and procurement frameworks.

Key company-level insights outlining strategic positioning, pipeline differentiation, collaborative ventures, and commercialization strategies across leading pneumonia therapeutics developers

Company-level dynamics are increasingly defined by a focus on pipeline differentiation, strategic partnerships, and commercialization agility rather than singular product launches. Developers that combine targeted anti-infective programs with adjunctive biologic approaches position themselves to address heterogeneous clinical needs while creating multiple levers for value demonstration. Licensing agreements and co-development partnerships are commonly used to accelerate access to complementary technologies, such as rapid diagnostics or inhalation delivery platforms, that strengthen clinical adoption pathways and improve time-to-market execution.

At the commercial interface, companies are investing in evidence generation beyond pivotal trials, emphasizing real-world data collection, health economics and outcomes research, and post-authorization safety monitoring to meet payer and clinician expectations. Manufacturing strategies are evolving to incorporate dual-sourcing and regional production capacity for critical inputs and devices to mitigate supply interruptions. Finally, corporate strategies increasingly reflect a blend of selective M&A to secure complementary capabilities, targeted geographic expansion to capture access opportunities, and flexible commercial models that support hospital procurement teams and community providers in diverse settings.

Actionable strategic recommendations for industry leaders to optimize clinical development, supply resilience, reimbursement engagement, and patient access for pneumonia care

Industry leaders must pursue a set of pragmatic, high-impact actions to sustain innovation while safeguarding access and affordability. First, aligning clinical development programs with payer evidence requirements by embedding health economic endpoints and real-world evidence collection into trial designs will facilitate reimbursement discussions and accelerate uptake in diverse healthcare settings. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing capacity, and strategic inventory management will reduce vulnerability to trade disruptions and logistic delays that affect both drug and device availability.

Third, companies should cultivate integrated partnerships with diagnostics providers and care delivery organizations to enable precision targeting of therapies and to support outpatient and home-based care models. Fourth, commercial strategies must balance tiered pricing and contracting flexibility with transparent value communication to hospitals, payers, and pharmacy channels. Fifth, embedding digital tools for adherence support, remote monitoring, and patient engagement can improve outcomes and create measurable value for health systems. By implementing these coordinated actions, organizations can simultaneously advance clinical innovation, reinforce access pathways, and create defensible commercial positions in a fragmented and rapidly evolving therapeutic landscape.

Transparent research methodology explaining data sources, validation approaches, stakeholder interviews, and analytical frameworks employed in assessing pneumonia therapeutic areas

This research employed a multi-method approach combining primary stakeholder engagement, secondary literature synthesis, and iterative validation to ensure robust, actionable insights. Data sources included published clinical literature, regulatory guidance documents, device and therapeutic technical briefs, procurement policies from diverse health systems, and public filings that illuminate strategic company behavior. Primary inputs were gathered through structured interviews with clinicians, hospital procurement specialists, lifecycle management experts, and commercial leaders who provided contextual detail on operational challenges and adoption drivers.

Analytical frameworks integrated qualitative thematic analysis with scenario mapping to identify risk factors and opportunity pathways across clinical, supply chain, and reimbursement dimensions. A validation layer reconciled conflicting signals by triangulating interview findings with documented regulatory precedents and technical specifications of devices and drug classes. Throughout the process, emphasis was placed on transparency in assumptions, traceability of evidence, and the reproducibility of key conclusions, ensuring that recommendations are grounded in observable practice and validated stakeholder perspectives.

A concluding synthesis that distills strategic imperatives, risk mitigations, and opportunity pathways for stakeholders engaged in pneumonia therapeutic development and delivery

The conclusion synthesizes the analysis into a set of strategic imperatives that guide organizations toward durable, patient-centered solutions in pneumonia therapeutics. Investment in targeted therapeutics and supportive care modalities must be paired with pragmatic operational strategies that preserve access amid supply chain and trade headwinds. Simultaneously, robust evidence generation that demonstrates clinical and economic value will be decisive in achieving broad adoption across varied care settings.

Risk mitigation requires proactive supply chain redesign, stronger partnerships across diagnostics and care delivery, and adaptable commercial approaches that respect regional heterogeneity. Opportunity lies in integrating diagnostics-driven therapeutics, expanding outpatient care capabilities, and leveraging digital health to enhance adherence and monitoring. Collectively, these imperatives form a coherent agenda for stakeholders seeking to advance therapeutic innovation while ensuring that clinical gains translate into measurable improvements in patient outcomes and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumonia Therapeutics Market, by Therapy Type

  • 8.1. Adjunctive Therapies
    • 8.1.1. Corticosteroids
    • 8.1.2. Nebulizers
  • 8.2. Anti Infectives
    • 8.2.1. Antibiotics
      • 8.2.1.1. Aminoglycosides
      • 8.2.1.2. Beta Lactams
      • 8.2.1.3. Macrolides
      • 8.2.1.4. Quinolones
      • 8.2.1.5. Tetracyclines
    • 8.2.2. Antifungals
    • 8.2.3. Antivirals
  • 8.3. Biologics
    • 8.3.1. Immune Modulators
    • 8.3.2. Monoclonal Antibodies
  • 8.4. Supportive Therapies
    • 8.4.1. Fluid Management
    • 8.4.2. Mechanical Ventilation
    • 8.4.3. Oxygen Therapy

9. Pneumonia Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral

10. Pneumonia Therapeutics Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Pneumonia Therapeutics Market, by Pathogen Type

  • 11.1. Atypical
    • 11.1.1. Chlamydophila
    • 11.1.2. Legionella
    • 11.1.3. Mycoplasma
  • 11.2. Bacterial
  • 11.3. Fungal
  • 11.4. Viral

12. Pneumonia Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Pneumonia Therapeutics Market, by Indication Type

  • 13.1. Community Acquired
  • 13.2. Hospital Acquired
  • 13.3. Ventilator Associated

14. Pneumonia Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Pneumonia Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pneumonia Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Pneumonia Therapeutics Market

18. China Pneumonia Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Allergan plc
  • 19.7. AstraZeneca PLC
  • 19.8. Aurobindo Pharma Limited
  • 19.9. Bayer AG
  • 19.10. Biobrick Pharma
  • 19.11. Cipla Limited
  • 19.12. Dr. Reddy's Laboratories Ltd.
  • 19.13. Eli Lilly and Company
  • 19.14. F. Hoffmann-La Roche Ltd.
  • 19.15. GlaxoSmithKline PLC
  • 19.16. Hikma Pharmaceuticals PLC
  • 19.17. Lincoln Pharmaceuticals Ltd.
  • 19.18. Lupin Pharmaceuticals, Inc.
  • 19.19. Mankind Pharma Ltd.
  • 19.20. Merck & Co., Inc.
  • 19.21. Novartis AG
  • 19.22. Pfizer Inc.
  • 19.23. Sanofi S.A.
  • 19.24. Seqirus UK Limited by CSL Limited
  • 19.25. Serum Institute of India
  • 19.26. Sun Pharmaceutical Industries Ltd.
  • 19.27. Teva Pharmaceutical Industries Ltd.
  • 19.28. Viatris Inc.
  • 19.29. Wellona Pharma
  • 19.30. Zydus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY OXYGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY CHLAMYDOPHILA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY LEGIONELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY MYCOPLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY VENTILATOR ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 250. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 251. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. GCC PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 291. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 297. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. G7 PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 302. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 303. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 308. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY ATYPICAL, 2018-2032 (USD MILLION)
  • TABLE 310. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. NATO PNEUMONIA THERAPEUTICS MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL PNEUMONIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES PNEUMONIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD